Cargando…

Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors

Clearing senescent cells extends healthspan in mice. Using a hypothesis‐driven bioinformatics‐based approach, we recently identified pro‐survival pathways in human senescent cells that contribute to their resistance to apoptosis. This led to identification of dasatinib (D) and quercetin (Q) as senol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yi, Tchkonia, Tamara, Fuhrmann‐Stroissnigg, Heike, Dai, Haiming M., Ling, Yuanyuan Y., Stout, Michael B., Pirtskhalava, Tamar, Giorgadze, Nino, Johnson, Kurt O., Giles, Cory B., Wren, Jonathan D., Niedernhofer, Laura J., Robbins, Paul D., Kirkland, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854923/ https://www.ncbi.nlm.nih.gov/pubmed/26711051 http://dx.doi.org/10.1111/acel.12445

Ejemplares similares

New agents that target senescent cells: the flavone, fisetin, and the BCL-X(L) inhibitors, A1331852 and A1155463
por: Zhu, Yi, et al.
Publicado: (2017)

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
por: Zhu, Yi, et al.
Publicado: (2015)

Identification of HSP90 inhibitors as a novel class of senolytics
por: Fuhrmann-Stroissnigg, Heike, et al.
Publicado: (2017)

Effect of Combined Dasatinib and Fisetin Treatment on Senescent Cell Clearance in Monkeys
por: Colman, Ricki, et al.
Publicado: (2020)

ORALLY ACTIVE, CLINICALLY TRANSLATABLE SENOLYTICS RESTORE Α-KLOTHO IN MICE AND HUMANS
por: Zhu, Yi, et al.
Publicado: (2022)

Senolytics: Potential for Alleviating Diabetes and Its Complications
por: Palmer, Allyson K, et al.
Publicado: (2021)

Senolytic drugs: from discovery to translation
por: Kirkland, J. L., et al.
Publicado: (2020)

Discovery, development, and future application of senolytics: theories and predictions
por: Wissler Gerdes, Erin O., et al.
Publicado: (2020)

Senolytics reduce coronavirus-related mortality in old mice
por: Camell, Christina D., et al.
Publicado: (2021)

Senolytics Improve Physical Function and Increase Lifespan in Old Age
por: Xu, Ming, et al.
Publicado: (2018)

Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
por: Zhu, Yi, et al.
Publicado: (2022)

Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity
por: González‐Gualda, Estela, et al.
Publicado: (2020)

ET-6 Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice
por: Roos, Carolyn M., et al.
Publicado: (2016)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
por: Sharma, Anuj K., et al.
Publicado: (2020)

Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation
por: Hernández-Silva, David, et al.
Publicado: (2022)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
por: Softah, Abrar, et al.
Publicado: (2023)

Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
por: Lafontaine, Julie, et al.
Publicado: (2021)

Targeting senescent cells enhances adipogenesis and metabolic function in old age
por: Xu, Ming, et al.
Publicado: (2015)

Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
por: Mohamad Anuar, Nur Najmi, et al.
Publicado: (2020)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

LGG-09. SENOLYTIC AGENT NAVITOCLAX TARGETS VINBLASTINE- AND MAPK INHIBITORS-INDUCED SENESCENT TUMOUR CELLS IN PAEDIATRIC LOW GRADE GLIOMAS
por: Guiho, Romain, et al.
Publicado: (2021)

SARS-CoV-2 causes senescence in human cells and exacerbates the senescence-associated secretory phenotype through TLR-3
por: Tripathi, Utkarsh, et al.
Publicado: (2021)

COVID-19 and cellular senescence
por: Schmitt, Clemens A., et al.
Publicado: (2022)

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
por: Justice, Jamie N., et al.
Publicado: (2019)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Fisetin is a senotherapeutic that extends health and lifespan
por: Yousefzadeh, Matthew J., et al.
Publicado: (2018)

Gemcitabine Cooperates with Everolimus to Inhibit the Growth of and Sensitize Malignant Meningioma Cells to Apoptosis Induced by Navitoclax, an Inhibitor of Anti-Apoptotic BCL-2 Family Proteins
por: Yamamoto, Masahiro, et al.
Publicado: (2022)

Fisetin for COVID‐19 in skilled nursing facilities: Senolytic trials in the COVID era
por: Verdoorn, Brandon P., et al.
Publicado: (2021)

Aging, Senescent Cells, and Senolytic Drugs: The Path to Translation
por: Kirkland, James
Publicado: (2020)

Deleted in Breast Cancer 1 Limits Adipose Tissue Fat Accumulation and Plays a Key Role in the Development of Metabolic Syndrome Phenotype
por: Escande, Carlos, et al.
Publicado: (2015)

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
por: Hickson, LaTonya J., et al.
Publicado: (2019)

Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer’s disease
por: Gonzales, Mitzi M., et al.
Publicado: (2023)

Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (SToMP-AD): A Pilot Clinical Trial
por: Gonzales, Mitzi M., et al.
Publicado: (2021)

Growth hormone in adipose dysfunction and senescence
por: Stout, Michael B., et al.
Publicado: (2015)

Senolytics improve muscle adaptation in old mice
por: Dungan, Cory M., et al.
Publicado: (2023)

Impact of Senolytic Treatment on Gene Expression in Aged Lung
por: Cho, Soo Jung, et al.
Publicado: (2023)

Cellular senescence mediates fibrotic pulmonary disease
por: Schafer, Marissa J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ad7ssb8dhat0moo2acqs54eqg3